• Explore /
  • Poster
  • / Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).

Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).

Abstract Poster

Authors

Adam Brufsky

Adam Brufsky

University of Pittsburgh Medical Center, Division of Hematology Oncology, Pittsburgh, PA

Adam Brufsky , Sung-Bae Kim , Zanete Zvirbule , Luc Yves Dirix , Alexandru E. Eniu , Francisco Carabantes , Yann Izarzugaza , Jeroen Mebis , Joohyuk Sohn , Matthew Wongchenko , Saibah Chohan , Reena Amin , V. A. McNally , David Miles , Sherene Loi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Triple-Negative

Clinical Trial Registration Number

NCT02322814

Citation

J Clin Oncol 37, 2019 (suppl; abstr 1013)

DOI

10.1200/JCO.2019.37.15_suppl.1013

Abstract #

1013

Poster Bd #

94

Abstract Disclosures

Similar Posters

First Author: Leisha A. Emens

First Author: Maria Cortes

First Author: Gang Jin

First Author: Peter Schmid